Skip to main content
. 2020 Jan 14;12(1):201. doi: 10.3390/cancers12010201

Figure 6.

Figure 6

Mechanistic mode of action effects of BAY-155 ex vivo. (A,B) Relative expression level of MEIS1, MNDA and CD11b after 17 or 11 days of treatment with BAY-155 or vehicle at the indicated dose in MV4;11 (A) or MOLM-13 (B) xenografts, respectively. (C) Relative expression level of FKBP5, TMPRSS2 and KLK2 after 52 days of treatment with BAY-155, enzalutamide or vehicle at the indicated dose in VCaP xenografts. (D) Relative expression level of EGR3, GREB1 and PGR1 after 27 days of treatment with BAY-155, tamoxifen or vehicle at the indicated dose in MCF7 xenografts. Data were normalized to 18S RNA and the average vehicle control. Significant difference between vehicle control and treatment group: * p-value ≤ 0.05, ** p-value ≤ 0.01, *** p-value ≤ 0.001, two-sided t-test.